NYSDOH Informational Message: Monoclonal Antibodies
“Monoclonal antibody treatments for Covid19 are no longer being distributed through a state allocation system. There is no shortage in supply of these drugs, and the U.S. Department of Health and Human Services (HHS) has enough on hand to meet the needs of all treatment facilities. For this reason, these therapies are now available through direct ordering only. All treatment sites meeting Emergency Use Authorization (EUA) requirements must now order Covid19 mAb therapies directly from AmerisourceBergen Corporation (ABC), the drugs’ sole distributor. The products remain free of charge to requesting sites.
HHS will continue to monitor all direct orders and retains the capacity to resume allocation of these and future therapies if needed. Treatment sites should review the direct ordering process guide and place orders directly with ABC at this site.
Please note that in addition to reporting therapeutics data in HHSProtect or the National Healthcare Safety Network, treatment sites wishing to place direct orders will be required to provide ABC with a board of pharmacy license or physician letter of authorization, attest to their designated class of trade, and ensure that product administration will be conducted according to the drugs’ EUAs.
Should you have any questions or concerns regarding the direct order process for COVID-19 monoclonal antibodies, you may contact HHS/ASPR at COVID19Therapeutics@hhs.gov or ABC at C19therapies@amerisourcebergen.com.”